Mandar Sanas

[Reena Thakur @5Reena_thakur]

Let’s connect with @brunolarvol and @Judith at #ASCO2026 💜🐯
Exploring the future of oncology and AI-driven healthcare innovation together in Chicago!
#ASCO #Oncology #PrecisionMedicine #AIinHealthcare #Diagnostics #CancerResearch #Larvol #HealthcareInnovation

[LARVOL @Larvol]

From bladder cancer to prostate and kidney cancer, several GU oncology studies are already generating strong attention ahead of @ASCO 2026.

To identify the trials most likely to shape discussions at the meeting, we asked leading AI models to rank the most anticipated GU cancer readouts.

There was particularly strong consensus around EV-302, PROTEUS, RAMPART, and TALAPRO-3 highlighting continued momentum for ADCs, radioligand therapy, immunotherapy combinations, and intensified hormonal strategies across GU cancers.

The list underscores key themes shaping the field:
▶️ Expansion of ADC and immunotherapy combinations in urothelial cancer
▶️ Continued evolution of AR-targeted and PARP-based approaches in prostate cancer
▶️ Growing momentum for radioligand and PSMA-targeted therapies
▶️ Increased focus on treatment optimization and de-escalation strategies
▶️ Novel approaches in RCC, NMIBC, and metastatic hormone-sensitive disease

Notable studies include:
• EV-302 evaluating enfortumab vedotin + pembrolizumab in metastatic urothelial cancer
• PROTEUS assessing apalutamide intensification in high-risk localized prostate cancer
• TALAPRO-3 advancing talazoparib-based combinations in HRR-altered mCSPC
• PSMAddition exploring 177Lu-PSMA-617 in PSMA-positive mHSPC
• RAMPART evaluating adjuvant durvalumab strategies in renal cell carcinoma

Together, these studies reflect how GU oncology continues to move toward more biomarker-driven, targeted, and combination-focused treatment strategies heading into ASCO 2026.

Which GU cancer trial are you watching most closely?

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUOncology #GUCancer #GUCSM #GenitourinaryCancer | @DrChoueiri | @neerajaiims | @AndreaNecchi | @UroDocAsh | @nataliagandur

[LARVOL @Larvol]

@ASCO 2026: Day 1 Preview

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology | @Erman_Akkus | @HadidiSamer | @PTarantinoMD | @neerajaiims | @Latinamd

[LARVOL @Larvol]

U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for TEPMETKO® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer

https://t.co/Q6ixptSYNG

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #LungCancer #NSCLC #FDA #FDAApproval #FoundationOneCDx #CompanionDiagnostic

[Debarati @Debarat07333230]

Roaring Tigers #larvol

[LARVOL @Larvol]

Celebrating Phuong Ly-Gallagher (@CancerInsider) for her dedication to improving support, awareness, and outcomes within the cancer community.

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #TimesSquare | @brunolarvol | @ejgallagher1

[LARVOL @Larvol]

@ASCO 2026: Abstracts are out!

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwnPG

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology | @tompowles1 | @CathyEngMD | @HHorinouchi | @ADesaiMD | @ErikaHamilton9 | @VincentRK

[LARVOL @Larvol]

Honoring our top-performing tigers with a special Times Square billboard spotlight. Thank you for your hard work, commitment, innovation, and leadership at @Larvol.

The top performers at #LARVOL: Judith Pérez Granado (@Jud_Prz) | Venkateshwaran T (@VENKATE34584054) | Haris Hassan | Sowmya Sannareddy

#CancerResearch #CancerData #Oncology #MedicalOncology #OncologyInsights #TimesSquare #NYC | Bruno Larvol (@brunolarvol)

[LARVOL @Larvol]

Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

https://t.co/IEH8NaIUEj

Learn more 👉 https://t.co/gQkEXOyIqK

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #BreastCancer #TNBC #mTNBC #BCSM #FDA #FDAApproval | @RebeccaDSing | @FernandoOnco | @ErikaHamilton9 | @hoperugo | @OncBrothers | @PTarantinoMD | @Dr_Oncologista

[ONCO BRUNO @brunolarvol]

The big one. See you there.

[LARVOL @Larvol]

@AACR 2026: Pre-Conference Preview

Explore more insights and data from #AACR26 👉 https://t.co/tU7pvaXmTP

#LARVOL #AACR2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @brunolarvol | @sallychurch | @AndreaAnampaG

[LARVOL @Larvol]

We're headed to Chicago, IL 🇺🇸, for @ASCO 2026 | May 29 - June 2

Explore more insights and conference data from #ACSO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology | @brunolarvol | @Jud_Prz

[LARVOL @Larvol]

We're headed to Frankfurt 🇩🇪 for Pharma CI Europe 2026 | April 29-30.

If you’re also attending, let’s connect!

Get data-driven and real-time insights with CLIN 👉 https://t.co/ct6tMIQHii

#LARVOL #PharmaCI #PharmaCIEurope #CompetitiveIntelligence #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology | @brunolarvol

[Reena Thakur @5Reena_thakur]

The LARVOL team is going to land in Copenhagen for #ELCC26! Be sure to connect with @brunolarvol at the conference to explore latest AI-driven oncology products and real-time cancer insights 🧬🤖 #LarvolAI #LungCancer #Copenhagen

[LARVOL @Larvol]

We're headed to Copenhagen, Denmark 🇩🇰, for European Lung Cancer Congress (ELCC 2026), March 25-28.

Explore more insights and conference data from #ELCC26 👉 https://t.co/PuWKbMIQiA

#LARVOL #ELCC2026 #LungCancer #LCSM #NSCLC #SCLC #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @brunolarvol | @Jud_Prz

[LARVOL @Larvol]

With ELCC 2026 upon us, oncologists are already weighing in, sharing, discussing, and debating the most anticipated lung cancer abstracts ahead of the meeting.

We’re tracking these conversations in real time, analyzing what’s gaining traction across the global oncology community. Here are the pre-conference Top abstracts for ELCC 2026.

Special thanks to Dr. Mike Thompson (@mtmdphd) for the original idea.

Which abstract are you watching at ELCC 2026?

Explore more insights and conference data from #ELCC26 E https://t.co/PuWKbMIQiA

#LARVOL #ELCC2026 #LungCancer #LCSM #NSCLC #SCLC #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials

Discussion threads:

Dr. Rishabh Jain (@DrRishabhOnco): https://t.co/y3AA2WrGwZ

Dr. Uğur Özkerim (@UOzkerim): https://t.co/2BE9vV0mUD

Dr. Hidehito Horinouchi (@HHorinouchi): https://t.co/VyfjrHDDRr

Dr. Amol Akhade (@SuyogCancer): https://t.co/asmgVqZpvO

[LARVOL @Larvol]

We asked leading AI models to simulate oncologist poll responses before the actual results were announced and compared their predictions to the original poll by Dr. Robert Orlowski (@Myeloma_Doc) on Multiple Myeloma 👉 https://t.co/zXWwslq22R

Across models, the AI consensus favored Dara-VRd (51%), followed by Isa-VRd (27%).

Clinicians were even more decisive, 65.6% selected Dara-VRd.

Both AI and oncologists converged on a clear signal: Fit, transplant-ineligible patients are increasingly treated with frontline quadruplets to maximize depth of response and MRD negativity.

Overall AI correctly identified the direction of frontline intensification — but underestimated how dominant Dara-VRd has become in real-world decision-making.

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #Myeloma #MultipleMyeloma #MMSM | @VincentRK | @RahulBanerjeeMD | @HadidiSamer | @Abdallah81MD

[ONCO BRUNO @brunolarvol]

See you there :)

[LARVOL @Larvol]

We're headed to Copenhagen, Denmark 🇩🇰 for European Lung Cancer Congress (ELCC) 2026, March 25-28.

If you are attending, let’s connect!

Get data-driven and real-time insights with CLIN 👉 https://t.co/ct6tMIQHii

#LARVOL #ELCC26 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #LungCancer #LCSM | @brunolarvol | @Jud_Prz

[LARVOL @Larvol]

We're headed to San Francisco, CA 🇺🇸, for @ASCO GU 2026, February 26-28.

If you are attending, let’s connect! Explore more insights and data from #GU26: https://t.co/hJxifSw7lM

#LARVOL #ASCOGU26 #CancerResearch #CancerData #Oncology #OncologyInsights #GUCancer #GenitourinaryCancer #GUCSM | @brunolarvol | @one_interrobang